This review evaluates the clinical efficacy of platelet-rich plasma therapy in dermatology, highlighting recent research findings and discussing its potential and limitations without reporting new clinical results.
This study observed that 5% minoxidil topical foam alters gene expression and signaling pathways in the scalp, providing insights into its mechanism of action in men with androgenetic alopecia.
35 citations
,
October 2014 in “Wound Repair and Regeneration”
This study developed a validated murine model of hypertrophic scar contraction, demonstrating similarities to human skin and observing graft contraction and tissue characteristics over time.
Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.
PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a newmechanism of action.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
Hair growth relies on mechanical forces, not just chemicals, with tissue acting like a motor. Minoxidil and finasteride help, but maintaining tissue elasticity and addressing mechanical issues are essential.